T1	Participants 48 166	patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events)
T2	Participants 211 240	Patients with type 2 diabetes
T3	Participants 570 609	high-risk patients with type 2 diabetes
T4	Participants 753 813	recruited patients from primary-care practices and hospitals
T5	Participants 2410 2484	patients with type 2 diabetes who have a high risk of macrovascular events
